IQVIA Holdings, Inc., headquartered in Durham, North Carolina, is an American company focused on health information technology and clinical research. The company operates three divisions: Technology & Analytics (40% of 2024 revenues), focused on health information technology with access to 1.2 billion unique non-identified patient records globally, offers cloud-based customer relationship management application software as well as analytics consulting services all to the healthcare industry; Research & Development (55% of 2024 revenues), which is a contract research organization that handles all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, post-approval services, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics; and Contract Sales & Medical (5% of 2024 revenues), which offers contract sales to healthcare providers and patient engagement services.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | 2025-12-02 08:00:02 | 228.5 | 0.01 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IQV | 0001478242 | IQVIA HOLDINGS INC. | US46266C1053 | 549300W3R20NM4KQPH86 | 271341991 | NYSE | 8731 | Services-Commercial Physical & Biological Research | 1231 | DE | 2400 ELLIS ROAD | DURHAM | NC | 27703 | UNITED STATES | US | 919-998-2000 | 2400 ELLIS ROAD, DURHAM, NC, 27703 | 2400 ELLIS ROAD, DURHAM, NC, 27703 | Quintiles IMS Holdings, Inc. | Contract Research Organization | 1982 | Ari Bousbib | 88,000 | http://iqvia.com | 38,200,000,000 | 258,800,000 | 170,300,000 | IQVIA Holdings, Inc., headquartered in Durham, North Carolina, is an American company focused on health information technology and clinical research. The company operates three divisions: Technology & Analytics (40% of 2024 revenues), focused on health information technology with access to 1.2 billion unique non-identified patient records globally, offers cloud-based customer relationship management application software as well as analytics consulting services all to the healthcare industry; Research & Development (55% of 2024 revenues), which is a contract research organization that handles all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, post-approval services, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics; and Contract Sales & Medical (5% of 2024 revenues), which offers contract sales to healthcare providers and patient engagement services. | 2025-11-27 14:55:45 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 38,200,000,000 | -2,600,000,000 | -6.3725 | 176,100,000 | -5,400,000 | -2.9752 |
| 2023 | 40,800,000,000 | 600,000,000 | 1.4925 | 181,500,000 | -4,222,621 | -2.2736 |
| 2022 | 40,200,000,000 | -5,500,000,000 | -12.035 | 185,722,621 | -4,762,643 | -2.5003 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Kevin C. Knightly | President | 2018 | 517,500 | 0 | 521,475 | 575,000 | 33,351 | 2,190,182 |
| Eric M. Sherbet | Secretary, Executive Vice President, General Counsel | 2018 | 415,833 | 0 | 294,676 | 350,000 | 63,939 | 1,399,451 |
| Ari Bousbib | President, Chairman, Chief Executive Officer | 2018 | 1,600,000 | 0 | 3,911,254 | 6,300,000 | 536,516 | 16,461,779 |
| Michael R. Mcdonnell | Chief Financial Officer, President, Executive Vice President | 2018 | 650,000 | 0 | 651,772 | 600,000 | 58,560 | 2,566,555 |
| James H. Erlinger | Secretary, Executive Vice President, General Counsel | 2018 | 122,500 | 0 | 59,745 | 0 | 2,168,162 | 2,404,214 |
| Fiscal Year | Employee Count |
|---|---|
| 2019 | 67,000 |
| 2018 | 58,000 |
| 2017 | 55,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 15,405,000,000 | 14,984,000,000 | 14,410,000,000 |
| Cost Of Revenue | 10,030,000,000 | 9,745,000,000 | 9,382,000,000 |
| Gross Profit | 1,522,000,000 | 1,490,000,000 | 1,550,000,000 |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | 1,992,000,000 | 2,053,000,000 | 2,071,000,000 |
| Operating Expenses | — | — | — |
| Operating Income | 2,202,000,000 | 1,977,000,000 | 1,799,000,000 |
| Net Income | 1,373,000,000 | 1,358,000,000 | 1,091,000,000 |
| Earnings Per Share Basic | 7.57 | 7.39 | 5.82 |
| Earnings Per Share Diluted | 7.49 | 7.29 | 5.72 |
| Weighted Average Shares Outstanding Basic | 181,300,000 | 183,800,000 | 187,600,000 |
| Weighted Average Shares Outstanding Diluted | 183,400,000 | 186,300,000 | 190,600,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,702,000,000 | 1,376,000,000 | 1,216,000,000 |
| Marketable Securities Current | 141,000,000 | 120,000,000 | 93,000,000 |
| Accounts Receivable | 3,204,000,000 | 3,381,000,000 | 2,917,000,000 |
| Inventories | — | — | — |
| Non Trade Receivables | 36,000,000 | 32,000,000 | 43,000,000 |
| Other Assets Current | 154,000,000 | 141,000,000 | 151,000,000 |
| Total Assets Current | 5,829,000,000 | 5,596,000,000 | 4,981,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 535,000,000 | 523,000,000 | 532,000,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 21,070,000,000 | 21,085,000,000 | 20,356,000,000 |
| Total Assets | 26,899,000,000 | 26,681,000,000 | 25,337,000,000 |
| Accounts Payable | 3,684,000,000 | 3,564,000,000 | 3,316,000,000 |
| Deferred Revenue | 1,779,000,000 | 1,799,000,000 | 1,797,000,000 |
| Short Term Debt | 1,145,000,000 | 718,000,000 | 152,000,000 |
| Other Liabilities Current | 193,000,000 | 294,000,000 | 152,000,000 |
| Total Liabilities Current | 6,957,000,000 | 6,491,000,000 | 5,578,000,000 |
| Long Term Debt | 12,838,000,000 | 12,955,000,000 | 12,595,000,000 |
| Other Liabilities Non Current | 668,000,000 | 698,000,000 | 671,000,000 |
| Total Liabilities Non Current | 13,875,000,000 | 14,078,000,000 | 13,994,000,000 |
| Total Liabilities | 20,832,000,000 | 20,569,000,000 | 19,572,000,000 |
| Common Stock | 11,143,000,000 | 11,028,000,000 | 10,898,000,000 |
| Retained Earnings | 6,065,000,000 | 4,692,000,000 | 3,334,000,000 |
| Accumulated Other Comprehensive Income | -1,038,000,000 | -867,000,000 | -727,000,000 |
| Total Shareholders Equity | 6,067,000,000 | 6,112,000,000 | 5,765,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 1,114,000,000 | 1,125,000,000 | 1,130,000,000 |
| Share Based Compensation Expense | 206,000,000 | 217,000,000 | 194,000,000 |
| Other Non Cash Income Expense | 0 | 0 | 10,000,000 |
| Change In Accounts Receivable | -182,000,000 | 388,000,000 | 421,000,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 115,000,000 | 267,000,000 | 427,000,000 |
| Change In Other Liabilities | 11,000,000 | 0 | -1,000,000 |
| Cash From Operating Activities | 2,716,000,000 | 2,149,000,000 | 2,260,000,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 602,000,000 | 649,000,000 | 674,000,000 |
| Acquisition Of Business | 735,000,000 | 876,000,000 | 1,315,000,000 |
| Other Investing Activities | -2,000,000 | -5,000,000 | -8,000,000 |
| Cash From Investing Activities | -1,444,000,000 | -1,603,000,000 | -2,006,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 1,423,000,000 | 1,052,000,000 | 470,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 1,350,000,000 | 992,000,000 | 1,168,000,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 960,000,000 | 2,709,000,000 | 2,025,000,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -878,000,000 | -382,000,000 | -329,000,000 |
| Change In Cash | 326,000,000 | 160,000,000 | -150,000,000 |
| Cash At End Of Period | 1,702,000,000 | 1,376,000,000 | 1,216,000,000 |
| Income Taxes Paid | 295,000,000 | 340,000,000 | 255,000,000 |
| Interest Paid | 589,000,000 | 556,000,000 | 379,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 7.57 | 7.39 | 5.82 |
| Price To Earnings Ratio | 25.959 | 31.3099 | 35.2045 |
| Earnings Growth Rate | 2.4357 | 26.9759 | 15.2475 |
| Price Earnings To Growth Ratio | 10.6576 | 1.1607 | 2.3089 |
| Book Value Per Share | 33.4639 | 33.2535 | 30.7303 |
| Price To Book Ratio | 5.8723 | 6.9581 | 6.6674 |
| Ebitda | 3,452,000,000 | 3,495,000,000 | 2,892,000,000 |
| Enterprise Value | 47,908,263,000 | 54,824,644,000 | 49,968,364,000 |
| Dividend Yield | 0.0399 | 0.0247 | 0.0122 |
| Dividend Payout Ratio | 1.0364 | 0.7747 | 0.4308 |
| Debt To Equity Ratio | 2.3048 | 2.2371 | 2.2111 |
| Capital Expenditures | 1,126,000,000 | 1,116,000,000 | 1,165,000,000 |
| Free Cash Flow | 1,590,000,000 | 1,033,000,000 | 1,095,000,000 |
| Return On Equity | 0.2263 | 0.2222 | 0.1892 |
| One Year Beta | 1.1756 | 1.2317 | 1.1909 |
| Three Year Beta | 1.1894 | 1.1473 | 1.1962 |
| Five Year Beta | 1.1952 | 1.1915 | 1.1705 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| DANHAKL JOHN G | Director | 2025-11-05 | 158 | A | 2,772 |
| Fasano Jim | Director | 2025-11-05 | 193 | A | 4,063 |
| GOGGINS COLLEEN A | Director | 2025-11-05 | 181 | A | 4,702 |
| Wims Morris Leslie | Director | 2025-11-05 | 146 | A | 4,735 |
| BOUSBIB ARI | Director | 2025-10-29 | 77,592 | A | 884,755 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| John Boozman | Senator | 2025-11-15 | Sale (Partial) | 2025-10-02 | Joint | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-02-27 | Purchase | 2025-02-13 | Joint | $15,001 - $50,000 |
| Markwayne Mullin | Senator | 2024-09-19 | Purchase | 2024-08-20 | Joint | $15,001 - $50,000 |
| John F Reed | Senator | 2019-03-18 | Sale (Full) | 2019-02-28 | Joint | $1,001 - $15,000 |
| John F Reed | Senator | 2019-03-18 | Sale (Full) | 2019-02-28 | Self | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Rob Bresnahan | 2025-05-31 | PA08 | Sale | 2025-05-15 | — | $1,001 - $15,000 |
| Rob Bresnahan | 2025-05-08 | PA08 | Purchase | 2025-04-08 | — | $15,001 - $50,000 |
| Rob Bresnahan | 2025-03-27 | PA08 | Sale | 2025-02-25 | — | $1,001 - $15,000 |
| Susie Lee | 2023-05-26 | NV03 | Sale | 2023-05-09 | Joint | $1,001 - $15,000 |
| Daniel Goldman | 2023-05-19 | NY10 | Sale (Partial) | 2023-04-10 | — | $15,001 - $50,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Strategic Advocates LLC | 2025-09-30 | 18,994 | 100 | 189.94 |
| JPMORGAN CHASE & CO | 2025-09-30 | 623,418,570 | 3,282,147 | 189.9423 |
| Kimelman & Baird, LLC | 2025-09-30 | 570 | 3 | 190 |
| TD Capital Management LLC | 2025-09-30 | 950 | 5 | 190 |
| CIBC Private Wealth Group LLC | 2025-09-30 | 250,474,554 | 1,318,704 | 189.9399 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Investment Managers Series Trust II | 2025-09-30 | Class K | FORKX | 78 | 14,815.32 | 0.0181 |
| Investment Managers Series Trust II | 2025-09-30 | Class I | FORTX | 78 | 14,815.32 | 0.0181 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class H | RYNHX | 607 | 115,293.58 | 0.0854 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class C | RYNCX | 607 | 115,293.58 | 0.0854 |
| RYDEX SERIES FUNDS | 2025-09-30 | Class A | RYANX | 607 | 115,293.58 | 0.0854 |